Apogem's two resets say more than its second new CLO

Creditflux reported on 11 September that Apogem has priced its second new CLO of 2026, its first fresh issue since January, and the same report notes that alongside MCF CLO 11 from early in the year the manager has also priced two mid-market CLO resets in 2026. That two-to-one ratio carries more information than the headline deal, because a reset reprices seasoned collateral rather than funding a new portfolio.

The structure became private credit's funding story of the summer for exactly that reason: our reporting tracked Onex, KKR, Ares and Kennedy Lewis repricing seasoned vehicles in a stretch that put nearly $2bn of US CLO resets through the market in August, while Neuberger's $508m fresh issue at 120bp showed new-issue demand still clearing at the tight end.

Apogem's own calendar is easier to read than the market's: two refinancings of liabilities already on the books, one new vehicle funded since January. That compresses the reset thesis into a single manager's year — the wave is building a permanent senior-secured funding market for private credit, and every repricing ratchets the structural cost of direct lending lower.

The sequence, though, muddies the causation: a manager that stayed out of the primary market for roughly eight months and then printed a second vehicle in September does not read as short of liability demand. The likelier shortage is collateral, and that reading matches what else has printed this month and last: a EUR60bn pipeline of new deals, two-thirds of it M&A-related, the pricing test for unitranche, and KKR's hire of a former EMEA debt capital markets head and a JPMorgan dealmaker for European credit — funding getting cheaper while asset sourcing turns into the harder problem. Cheap liabilities are the solved half of the trade; resets are what a manager reaches for when the funding is in hand but the loan book is not yet large enough to justify another vehicle.

The counterweight sits in that same pipeline, where two-thirds of the EUR60bn queue is acquisition finance and M&A-driven supply is the likeliest source of the next batch of CLO collateral; if that volume lands, managers get both a reason to print new vehicles and loans to put inside them.

The Apogem item carries no size or spread, and the coverage does not say where the deal cleared or who arranged it, leaving no way to judge whether Apogem paid up against August's prints or took advantage of them.

Watch the fourth-quarter new-issue calendar. A thin one would confirm that most of the new capacity private credit built this year came from refinancing collateral it already owned, and that origination, rather than the investor bid for senior paper, is the variable that decides how much more of it gets built.